Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | EVP, Chief Business Officer | January 02, 2020 | January 03, 2020 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director · Chief Executive Officer | September 15, 2026 | September 16, 2026 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date January 02, 2020 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,316 |
Ending reported balance
After 2020-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-02 · Sale · Disposed 1,600 · Balance 57,558 F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 2 · 2020-01-02 · Sale · Disposed 4,242 · Balance 53,316 F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.83 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.84 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Disc Medicine, Inc.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,064 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 36,000 · Balance 262,064 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-03-10 | Direct | 150,120 |
Reported balance
After 2026-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Disposed 36,000 · Balance 150,120 F1: The shares underlying this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option are fully vested and exercisable as of the date hereof.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 10,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 10,000 · Balance 10,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2017 Filed Sep 14, 2017 17:03 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 600 | $39.37 | $23,622.00 |
DisclosureSEC source: 0001179110-17-012289 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,318 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.92 to $39.82 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:03 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 4,505 | $38.29 | $172,496.45 |
DisclosureSEC source: 0001179110-17-012289 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Corp. Dev., GC & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,918 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 46,300 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-17-004591 · edgar.xml · derivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,300 Underlying: Common Stock · 46,300 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 18:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 7,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004591 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,423 Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,400 | $27.56 | $38,584.00 |
DisclosureSEC source: 0001179110-17-000683 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,523 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.13 to $27.79 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:13 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 300 | $26.43 | $7,929.00 |
DisclosureSEC source: 0001179110-17-000683 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,923 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.98 to $26.94 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 11,500 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · derivative · entry 7 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 11,500 shares Expires 2020-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 13,671 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · derivative · entry 6 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,329 Underlying: Common Stock · 13,671 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 781 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · derivative · entry 5 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 781 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 45,952 | $38.05 | $1,748,473.60 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · nonDerivative · entry 4 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,223 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.40 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 11,500 | $3.88 | $44,620.00 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 13,671 | $24.11 | $329,607.81 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:09 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 781 | $7.12 | $5,560.72 |
DisclosureSEC source: 0001179110-16-030002 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 4,688 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · derivative · entry 7 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,343 Underlying: Common Stock · 4,688 shares Expires 2022-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 6,250 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · derivative · entry 6 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2022-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,500 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · derivative · entry 5 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires 2020-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 21,438 | $32.14 | $689,017.32 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · nonDerivative · entry 4 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,223 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.38 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 4,688 | $7.12 | $33,378.56 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · nonDerivative · entry 3 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 6,250 | $5.28 | $33,000.00 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · nonDerivative · entry 2 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 16:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 5,500 | $3.88 | $21,340.00 |
DisclosureSEC source: 0001179110-16-029591 · edgar.xml · nonDerivative · entry 1 Quisel John D · CIK 0001586788 · SVP, Bus. Dev., GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.